申请人:The Board of Regents of the University of Oklahoma
公开号:US20200071264A1
公开(公告)日:2020-03-05
Benzylamino-oxoethyl benzamide compounds for use in treating diseases and conditions associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic β-cell dysfunction and death, for example in the treatment of Type 1 and Type 2 diabetes. The compounds can also be used in treatments for chronic heart disease, neurodegenerative diseases, retinal degeneration, and other metabolic disorders associated with ER stress.
苯甲氨基氧乙基苯甲酰胺化合物,用于治疗与内质网(ER)应激相关的异常细胞功能所致的疾病和病况。例如,这些化合物可用作ER应激诱导的胰岛素β细胞功能障碍和死亡的抑制剂,例如用于治疗1型和2型糖尿病。这些化合物还可用于治疗慢性心脏病、神经退行性疾病、视网膜退化和其他与ER应激相关的代谢性疾病。